

APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052

Purchase of own shares - 1st Interim notification

Monheim am Rhein, 21 March 2022. In the period from 15 March 2022 up to and including 18 March 2022, a total of 10,464 shares were purchased under the Share Buyback Program 2022. The launch and the details of the Share Buyback Program 2022 were published by way of an announcement dated 15 March 2022 pursuant to Article 5 paragraph 1 of Regulation (EU) No. 596/2014 and Article 2 paragraph 1 of the Delegated Regulation (EU) No. 2016/1052.

The total number of shares purchased in the period from 15 March 2022 up to and including 18 March 2022 per day, exchange, average price and volume in euros are as follows:

Date	Total number of shares purchased (number)	Average price (Euro)	Exchange	Volume (EUR) ¹
15/03/2022	2,518	13.2170	Xetra	33,280.50
16/03/2022	2,648	12.9127	Xetra	34,192.90
17/03/2022	2,404	12.4994	Xetra	30,048.50
18/03/2022	2,894	12.3893	Xetra	35,854.60

1) Excluding acquisition costs

The total number of shares purchased to date as part of the Share Buyback Program 2022 up to and including 18 March 2022 amounts to 10,464 shares.

The share buyback was carried out by Hauck Aufhäuser Lampe Privatbank AG.

Further details on the Share Buyback Program 2022 and the above transactions are published under the Corporate Governance section of the Company's Investor Relations website in accordance with Article 5 of Regulation (EU) No. 596/2014 and



pursuant to Delegated Regulation (EU) No. 2016/1052 (<https://ir.apontis-pharma.de/websites/apontispharma/English/4000/corporate-governance.html>).